Skip to content

raghavagps/MDRIpred

Folders and files

NameName
Last commit message
Last commit date

Latest commit

 

History

3 Commits
 
 
 
 

Repository files navigation

MDRIPred: Predicting Inhibitors Against Drug-Tolerant Mycobacterium tuberculosis

Welcome to the official repository for MDRIPred, a computational platform developed for predicting inhibitors against drug-tolerant Mycobacterium tuberculosis (H37Rv). The system was designed to identify compounds effective against both replicative and non-replicative phases of tuberculosis under carbon starvation conditions.

This platform supports tuberculosis drug discovery by integrating machine learning, molecular fingerprints, pharmacophore analysis, and structural feature analysis.

Web Server: http://crdd.osdd.net/oscadd/mdri/


Citation

Singla, D., Tewari, R., Kumar, A., & Raghava, G. P. S. (2013).
Designing of inhibitors against drug tolerant Mycobacterium tuberculosis (H37Rv).
Chemistry Central Journal, 7, 49.
https://doi.org/10.1186/1752-153X-7-49 https://doi.org/10.5281/zenodo.20081512

About the Study

Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb), remains one of the deadliest infectious diseases worldwide. The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains has created an urgent need for discovering new anti-tubercular compounds.

This study focuses on identifying inhibitors effective against:

  • Replicative phase M.tb
  • Non-replicative (drug-tolerant) phase M.tb

The computational models were developed using high-throughput screening datasets and machine learning approaches to accelerate anti-tuberculosis drug discovery.


Dataset Information

The datasets were obtained from PubChem BioAssay screens:

  • AID-492952 (Replicative phase)
  • AID-488890 (Non-replicative phase)

Replicative Dataset (Rep_dataset)

  • Total compounds: 2135
  • Inhibitors: 1355
  • Non-inhibitors: 780

Non-Replicative Dataset (NRep_dataset)

  • Total compounds: 2135
  • Inhibitors: 1206
  • Non-inhibitors: 929

The compounds were processed after removing salts and ion-containing molecules.


Key Features

Machine Learning Models

Support Vector Machine (SVM)-based classification models were developed using multiple molecular fingerprint classes:

  • PubChem fingerprints
  • MACCS fingerprints
  • EState fingerprints
  • SubStructure fingerprints

The models predict whether a compound acts as an inhibitor or non-inhibitor against drug-tolerant M.tb.


Best Model Performance

Replicative Phase

  • Best MCC: 0.45
  • Best model: MACCS fingerprint model
  • Accuracy: ~73%

Non-Replicative Phase

  • Best MCC: 0.28
  • Best model: Hybrid fingerprint model
  • Accuracy: ~64%

Molecular Property Analysis

The study identified important physicochemical properties associated with anti-tubercular activity.

Important Descriptors

  • Molecular weight
  • Polar surface area (PSA)
  • Hydrogen bond acceptor count
  • Rotatable bond count
  • logP

Important Observations

Replicative Phase Inhibitors

Preferred properties include:

  • Molecular weight > 300 Da
  • Hydrogen bond acceptor > 5
  • Rotatable bond count > 6
  • Polar surface area > 88 Ų

Non-Replicative Phase Inhibitors

Preferred properties include:

  • Molecular weight < 380 Da
  • Rotatable bond count between 2–4

These rules may assist researchers in designing new anti-tubercular molecules.


Substructure Fragment Analysis

Substructure fragment analysis identified important molecular motifs associated with inhibitory activity.

Important Fragments in Replicative Inhibitors

  • hetero_N_nonbasic
  • heterocyclic
  • carboxylic_ester
  • hetero_N_basic_no_H

Important Fragments in Non-Replicative Inhibitors

  • hetero_O
  • ketone
  • secondary_mixed_amine
  • vinylogous_halide

Common Important Fragments

The following fragments were important in both phases:

  • Nitro
  • Alkyne
  • Enamine

SMART Filtering

SMART filtering was applied using:

  • Abbott ALARM filters
  • Glaxo filters
  • Pfizer LINT filters

This analysis helped identify undesirable chemical fragments related to toxicity and poor drug-like properties.


Pharmacophore Analysis

Pharmacophore models were generated using first-line and second-line anti-tubercular drugs including:

  • Rifampicin
  • Ethambutol
  • Streptomycin
  • Ethionamide
  • Cycloserine
  • Kanamycin
  • Amikacin

These pharmacophore models were used to identify structurally similar compounds within the datasets.


Feature Selection Algorithm

The study introduced a novel feature selection method called:

MCCA (Matthews Correlation Coefficient Algorithm)

MCCA was used for selecting informative fingerprints and descriptors for model development.

The method showed performance comparable or superior to frequency-based feature selection methods.


Web Server Features

The MDRIPred webserver allows users to:

  • Predict inhibitors against drug-tolerant M.tb
  • Analyze compounds for replicative and non-replicative activity
  • Perform pharmacophore similarity analysis
  • Upload molecular structures
  • Draw structures using JME editor

Input Submission Options

Users can submit molecules using:

  • JME molecular editor
  • MOL/MOL2 file format
  • File upload option

Technologies Used

The webserver was developed using:

  • Linux environment
  • CGI-Perl scripts
  • SVMlight package
  • PaDEL descriptor software
  • Pharmagist software

Applications

MDRIPred can be used for:

  • Anti-tuberculosis drug discovery
  • Virtual screening
  • Lead optimization
  • QSAR studies
  • Molecular property analysis
  • Pharmacophore screening
  • Drug resistance research

Availability

The webserver is freely available for academic and research purposes.

Web Server:
http://crdd.osdd.net/oscadd/mdri/


Contact

Prof. Gajendra P. S. Raghava

Bioinformatics Centre
CSIR-Institute of Microbial Technology
Chandigarh, India

Email: raghava@iiitd.ac.in


License

This work is distributed under the
Creative Commons Attribution License


Acknowledgements

The authors acknowledge support from:

  • Council of Scientific and Industrial Research (CSIR)
  • Open Source Drug Discovery (OSDD)
  • Department of Biotechnology (DBT)
  • Government of India

We also acknowledge the PubChem BioAssay resource and the scientific community contributing to tuberculosis drug discovery research.

About

MDRIPred: Predicting Inhibitors Against Drug-Tolerant Mycobacterium tuberculosis

Topics

Resources

License

Stars

Watchers

Forks

Packages

 
 
 

Contributors